Stock Analiz

Lakefront Biotherapeutics NV (LKFT) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Lakefront Biotherapeutics NV’s revenue went from $160M in fiscal 2016 to $1.3B in fiscal 2025, growth of about 26.3% a year.

Net income in fiscal 2025 was $377M, a net margin of 28.9%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $1.0B and net income $877M.

Free cash flow was -$319M in fiscal 2025 and positive in 2 of the 10 years shown.

Revenue, profit and cash flow by year

Revenue
2016: $160M162017: $187M172018: $352M182019: $995M192020: $651M202021: $265M212022: $257M222023: $265M232024: $286M242025: $1.3B25$1.3B
Net income
2016: $57M162017: -$139M172018: -$34M182019: $168M192020: -$375M202021: -$117M212022: -$233M222023: $234M232024: $77M242025: $377M25$377M
Free cash flow
2016: $248M162017: -$183M172018: -$175M182019: $3.6B192020: -$577M202021: -$632M212022: -$563M222023: -$469M232024: -$350M242025: -$319M25-$319M
EPS (diluted)
2016: $0.86162017: $-2.11172018: $-0.51182019: $2.55192020: $-5.69202021: $-1.77212022: $-3.53222023: $3.55232024: $1.17242025: $5.7225$5.72

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$1.0B$1.3B$286M$265M$257M$265M$651M$995M$352M$187M$160M
Gross profit—$1.3B$250M—$244M$264M—————
Operating income—$347M-$196M-$98M-$140M-$194M-$219M$414M-$54M-$108M-$12M
Net income$877M$377M$77M$234M-$233M-$117M-$375M$168M-$34M-$139M$57M
EPS (diluted)$13.25$5.72$1.17$3.55$-3.53$-1.77$-5.69$2.55$-0.51$-2.11$0.86
R&D———————————
Revenue growth—+356.4%+8.1%+2.9%−3.1%−59.2%−34.6%+182.5%+88.4%+17.0%+142.3%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow-$220M-$303M-$332M-$449M-$534M-$571M-$524M$3.6B-$163M-$176M$252M
Capital spending-$2M-$16M-$17M-$21M-$29M-$61M-$52M-$25M-$12M-$6M-$5M
Free cash flow-$222M-$319M-$350M-$469M-$563M-$632M-$577M$3.6B-$175M-$183M$248M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay—$28M$21M$63M$94M$80M$98M$43M$31M$20M$12M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$40M$727M$34M$97M$808M—$657M$320M$241M—
Debt—$0—————$0——$0
Equity—$3.8B$3.0B$3.1B$2.7B$3.0B$3.3B$3.2B$1.4B$1.2B$800M
Total assets—$4.0B$4.3B$4.8B$5.0B$5.9B$7.0B$6.8B$1.6B$1.5B$1.1B
Shares (diluted)66M66M66M66M66M66M66M66M66M66M66M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin—97.3%87.4%—95.0%99.3%—————
Operating margin—26.5%-68.3%-36.8%-54.3%-73.2%-33.7%41.6%-15.3%-57.6%-7.6%
Net margin85.9%28.8%26.9%88.3%-90.4%-44.0%-57.6%16.9%-9.5%-74.2%35.6%
FCF margin-21.7%-24.4%-122.2%-177.2%-218.8%-238.1%-88.6%359.7%-49.7%-97.7%155.0%
ROIC—7.2%-5.1%-2.5%-4.1%-5.1%-5.3%10.1%-3.1%-7.0%-1.5%
ROE—9.9%2.6%7.6%-8.6%-3.9%-11.4%5.2%-2.4%-11.4%7.1%

Frequently asked questions

What is Lakefront Biotherapeutics NV’s annual revenue?

$1.3B in fiscal 2025 and $1.0B over the twelve months to September 30, 2026.

How much profit does Lakefront Biotherapeutics NV make?

Net income was $377M in fiscal 2025 (net margin 28.9%).

Is Lakefront Biotherapeutics NV’s revenue growing?

Yes: revenue rose 356.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.